Dapagliflozin (5mg), Vildagliptin SR (50mg) h

Dapagliflozin (5mg), Vildagliptin SR (50mg)

DAPA VILDA 

1. Dapagliflozin (5mg):

   • Dapagliflozin belongs to a class of medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by blocking the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By inhibiting SGLT2, dapagliflozin promotes the excretion of excess glucose through the urine, thereby lowering blood sugar levels.
   • Dapagliflozin is typically taken orally once daily, with or without food.
   • Common side effects of dapagliflozin may include urinary tract infections, genital yeast infections, increased urination, dehydration, dizziness, and low blood pressure. It may also increase the risk of urinary tract and genital infections, particularly in women.

2. Vildagliptin SR (50mg):

   • Vildagliptin belongs to a class of medications known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by inhibiting the enzyme DPP-4, which is responsible for the degradation of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). By inhibiting DPP-4, vildagliptin prolongs the action of GLP-1 and GIP, which stimulate insulin release in response to meals and suppress glucagon secretion, leading to improved blood sugar control.
   • Vildagliptin is available in both immediate-release (IR) and sustained-release (SR) formulations. The sustained-release formulation (Vildagliptin SR) is designed to provide more consistent blood levels of the medication over time.
   • Common side effects of vildagliptin may include headache, upper respiratory tract infections, nasopharyngitis, and mild gastrointestinal symptoms such as nausea and diarrhea.